Bergmann Anthony

Nile Therapeutics, Inc

Chief Financial Officer

Avg. Two Year Performance

(25%) Avg. Purchase Return (12%) Compound

No Sale Track Record

Holdings: 2.38K shares

Last Three Months: 26-Aug-24 -- 25-Nov-24

0 Net Amount

Buy:	0	--
Sell:	0	--

Sentiment

Company Sentiment

Biotechnology

Drugs

Two Year Chart

26-Nov-22 -- 25-Nov-24

Price ($)

Two Year Stock Price Chart

Sentiment

Company Sentiment

Most Recent Insider Transactions